182 related articles for article (PubMed ID: 15291357)
21. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
22. [Disappearance of residual disease confirmed by RT-PCR following induction chemotherapy in two hypoplastic leukemia patients with t(8;21)].
Sawada M; Tsurumi H; Yamada T; Hara T; Oyama M; Moriwaki H
Rinsho Ketsueki; 1999 Apr; 40(4):311-7. PubMed ID: 10355140
[TBL] [Abstract][Full Text] [Related]
23. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
24. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
25. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia.
Garg M; Moore H; Tobal K; Liu Yin JA
Br J Haematol; 2003 Oct; 123(1):49-59. PubMed ID: 14510942
[TBL] [Abstract][Full Text] [Related]
27. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of detection of AML1/ETO fusion transcripts in childhood AML using real-time quantitative reverse transcription polymerase chain reaction].
Liu CF; Liu GL; Zhang LP; Cheng YF; Lu AD; Tian KG; Liu YR; Qin YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):76-82. PubMed ID: 15748440
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
Inokuchi K; Iwakiri R; Futaki M; Hanawa H; Tanosaki S; Nomura T; Dan K
Leuk Lymphoma; 1998 May; 29(5-6):553-61. PubMed ID: 9643569
[TBL] [Abstract][Full Text] [Related]
32. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and monitoring of AML1-MTG8 (ETO)-positive acute myeloid leukemia by qualitative and real-time quantitative RT-PCR.
Tobal K; Liu Yin JA
Methods Mol Med; 2006; 125():149-61. PubMed ID: 16502583
[TBL] [Abstract][Full Text] [Related]
34. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay.
Muto A; Mori S; Matsushita H; Awaya N; Ueno H; Takayama N; Okamoto S; Kizaki M; Ikeda Y
Br J Haematol; 1996 Oct; 95(1):85-94. PubMed ID: 8857943
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia.
Miyamoto T; Nagafuji K; Harada M; Eto T; Fujisaki T; Kubota A; Akashi K; Mizuno S; Takenaka K; Kanaji T
Br J Haematol; 1995 Sep; 91(1):132-8. PubMed ID: 7577620
[TBL] [Abstract][Full Text] [Related]
36. AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications.
Abdel Rahman H; Farrag SA; El-Attar IA
J Egypt Natl Canc Inst; 2007 Mar; 19(1):39-47. PubMed ID: 18839034
[TBL] [Abstract][Full Text] [Related]
37. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease in acute myeloid leukaemia.
Liu Yin JA
Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
[TBL] [Abstract][Full Text] [Related]
39. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
40. Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR.
Tobal K; Liu Yin JA
Leuk Lymphoma; 1998 Sep; 31(1-2):115-20. PubMed ID: 9720721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
